Report Category

Pharmaceutical Market Research Reports

In-depth market intelligence covering drug development, CDMO outsourcing, API manufacturing, biosimilars, oncology, cell & gene therapy, clinical trials, and specialty pharma — with 10-year forecasts, 15–25 KOL interviews per report, and competitive landscape analysis.

340+
Reports
10yr
Forecasts
15–25
KOL Interviews

Pharmaceutical Industry Market Intelligence

The global pharmaceutical market continues to evolve rapidly, driven by the acceleration of biologics and biosimilar development, the expansion of CDMO outsourcing models, advances in cell and gene therapy manufacturing, and the growing demand for complex drug delivery systems. InsightAce Analytic's pharmaceutical report library covers the full value chain — from active pharmaceutical ingredient sourcing and continuous manufacturing to clinical trial logistics and post-market commercialization.

CDMO & Contract ManufacturingOutsourcing models, capacity analysis, competitive positioning
API & Drug SubstanceSupply chain, HPAPI, peptide APIs, oligonucleotides
Oncology & Immuno-OncologyADCs, bispecifics, CAR-T, radiopharmaceuticals
Drug Delivery SystemsLNP platforms, nasal, transdermal, implantable devices
Biosimilars & BiologicsPatent cliffs, pipeline analysis, market penetration
Cell & Gene TherapyManufacturing, logistics, vein-to-vein supply chain
Clinical Trials & CRODecentralized trials, site management, real-world evidence
Rare Diseases & Orphan DrugsRegulatory pathways, pricing, competitive dynamics
CNS & NeurologyNeurodegeneration, psychiatric, digital therapeutics

Recombinant Human Endostatin Market Size, Share & Trends Analysis Report By Type (purity 95% and others) And By Application (medical care, scientific research and others), By Region, And By Segment Forecasts, 2024-2031

The Recombinant Human Endostatin Market Size is valued at USD 133.3 Mn in 2023 and is predicted to reach USD 249.4 Mn by the year 2031 at a 8.3% CAGR during the forecast period for 2024-2031. Recombinant human endostatin is a naturally occurring protein in the human body that prevents angiogenesis and has been bioengineered. Genetic engineering methods are used to generate the recombinant form for medical uses. The increasing number of cancer ...

ID: 2597 180 Pages July 2024

Radionuclide Drug Conjugates (RDC) Market Size, Share & Trends Analysis Distribution by Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma) and Segment Forecasts, 2024-2031

Radionuclide Drug Conjugates (RDC) Market Size is predicted to witness a 13.9% of CAGR during the forecast period for 2024-2031. Radionuclide Drug Conjugates (RDCs) represent a promising innovation in cancer treatment, utilizing a targeted approach to deliver radiation directly to tumor cells. By combining a radionuclide, targeting molecule, chelator, and linker, RDCs minimize harm to healthy tissues while effectively attacking cancer. This ta...

ID: 2567 180 Pages July 2024

Disseminated Intravascular Coagulation (DIC) Market Size, Share & Trends Analysis Report By Symptoms (Bleeding, Blood Clots, Bruising, Drop in Blood Pressure, Shortness of Breath, Confusion, Fever), Treatment (Medicines, Transfusions, Surgery), Diagnosis (Complete Blood Count with Blood Smear Exam, Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Fibrinogen Blood Test, D-dimer), Route of Administration, End-Users, Distribution Channel, By Region, And By Segment Forecasts, 2024-2031.

Disseminated Intravascular Coagulation (DIC) Market Size is valued at USD 437.3 Mn in 2023 and is predicted to reach USD 563.8 Mn by the year 2031 at a 3.3% CAGR during the forecast period for 2024-2031. The Disseminated Intravascular Coagulation (DIC) market focuses on managing a serious condition characterized by abnormal blood clotting, involving key segments such as diagnostics (e.g., D-dimer tests), therapeutics (anticoagulants and blood ...

ID: 2573 180 Pages July 2024

Long Acting Drug Delivery Technologies Services Market Size, Share & Trends Analysis Report By Technique (Long-Acting Injectables, Long-Acting Hydrogels, Long-Acting Implants, Long-Acting Microneedles, And Nanocrystal Suspensions), Dosage Form (Injectables, Implantable, Topical/Transdermal, Vaginal), Type Of Molecule Delivered, Material Used And End-User, Region And Segment Forecasts, 2023-2031

Global Long Acting Drug Delivery Technologies Services Market Size is valued at USD 13.7 Bn in 2023 and is predicted to reach USD 30.2 Bn by the year 2031 at a 10.6% CAGR during the forecast period for 2024-2031. The global long-acting drug delivery technologies and services market is witnessing robust growth due to the demand for improved patient adherence and therapeutic outcomes. Long-acting formulations, including injectables and implants,...

ID: 2565 180 Pages July 2024

Insulin-like Growth Factors Market Share & Trends Analysis Report, By Type (Mechano Growth Factor, Somatomedin C, IGF 1), By End-user (Hospitals, Medical Centers), By Region, and Segment Forecasts, 2023-2031

Insulin-like Growth Factors Market Size is valued at USD 275.1 Mn in 2023 and is predicted to reach USD 406.1 Mn by the year 2031 at an 5.13% CAGR during the forecast period for 2024-2031. Insulin-like growth factors (IGFs) are proteins that resemble insulin in structure and share some of its effects. Their primary function, however, is to stimulate cell growth and development throughout the body, forming part of a complex system known as the ...

ID: 2561 180 Pages July 2024

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Size, Share & Trends Analysis by Disease (Neurological Disorders and Dystrophies, Cardiac disorders, Retinal Eye Disease, Metabolic Disorders, Liver disease, Others), Products and Services (Disease Model, Reprogramming service, Differentiation service, Screening service, Characterization service, Others), and Segment Forecasts, 2023-2031

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model   Market Size is predicted to grow at an 11.2% CAGR during the forecast period for 2024-2031. Human-induced pluripotent stem cells (hiPSCs) are a pivotal tool in biomedical research, particularly for preclinical disease modelling and drug development. Derived from adult somatic cells like skin or blood cells, hiPSCs are reprogrammed to an embryonic-like pluripote...

ID: 2556 180 Pages July 2024

VEGFR-1 Inhibitors Market Size, Share & Trends Analysis Report, By Drug Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and Others), By Application (Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, and Other), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region, Forecasts, 2024-2031

VEGFR-1 Inhibitors Market Size is predicted to grow at a 7.0% CAGR during the forecast period for 2024-2031. VEGFR-1 inhibitors are essential in treating various cancers by targeting the vascular endothelial growth factor receptor-1, which is crucial for angiogenesis and tumor growth. The increasing prevalence of cancer and advancements in targeted therapies are expected to drive the adoption of VEGFR-1 inhibitors. Additionally, ongoing resear...

ID: 2552 180 Pages June 2024

Cephalosporin API Market Size, Share & Trends Analysis Report By Product Type (First Generation, Second Generation, Third Generation, Fourth Generation), By Formulation (Oral, Injection), By Consumer Type (Hospital Use, Clinic Use, Recovery Center), By Region, And By Segment Forecasts, 2024-2031.

Cephalosporin API Market Size is valued at USD 1.70 billion in 2023 and is predicted to reach USD 2.62 billion by the year 2031 at a 5.7% CAGR during the forecast period for 2024-2031. Cephalosporin APIs are the active pharmaceutical ingredients derived from fungi, specifically Acremonium, and they form the basis of cephalosporin antibiotics like cephalexin and ceftriaxone. These APIs are crucial for treating bacterial infections and undergo r...

ID: 2547 180 Pages June 2024

Thymidylate Synthase Inhibitor Market Size, Share & Trends Analysis Report By Type (Injection, Tablet, Others), By Application (Hospital, Clinic, Others), By Region, And By Segment Forecasts, 2024-2031.

Thymidylate Synthase Inhibitor Market Size is predicted to grow at a 6.0% CAGR during the forecast period for 2024-2031. Thymidylate synthase inhibitors disrupt DNA synthesis by blocking the enzyme thymidylate synthase. They are used primarily in cancer treatment to inhibit the growth of cancer cells, which rely on rapid DNA replication. Examples include 5-fluorouracil (administered intravenously), pemetrexed (also intravenous), and raltitrexe...

ID: 2549 180 Pages June 2024

cDNA Clone Vectors Market Size, Share & Trends Analysis Report By Type (Rat, Cat, Dog, Monkey, Human, Others), By Application (BioScience Companies, Hospital and Clinics, University and Institutions, Others), By Region, And By Segment Forecasts, 2024-2031.

cDNA Clone Vectors Market Size is valued at USD 120.8 Mn in 2023 and is predicted to reach USD 258.1 Mn by the year 2031 at a 10.2% CAGR during the forecast period for 2024-2031. cDNA clone vectors are tools used in molecular biology to clone and express complementary DNA (cDNA) derived from messenger RNA (mRNA). These vectors typically contain elements such as promoter regions for gene expression, selection markers for identifying successfull...

ID: 2544 180 Pages June 2024

Key Pharmaceutical Sub-Segments We Cover

CDMO & Contract Manufacturing

The pharmaceutical CDMO market is expanding rapidly as drug developers increasingly outsource manufacturing to reduce capital expenditure and accelerate time-to-market. Our CDMO reports cover small molecule contract manufacturing, biologics CDMO, fill-finish services, and continuous manufacturing outsourcing with competitive landscape analysis of leading CDMOs worldwide.

API & Drug Substance Manufacturing

Active pharmaceutical ingredient sourcing and manufacturing is a critical strategic decision for pharma companies. Our API reports analyze supply chain dynamics, pricing trends, geographic manufacturing shifts, and the growing demand for high-potency APIs, peptide APIs, and oligonucleotide synthesis.

Drug Delivery Systems

Innovation in drug delivery — from nasal and transdermal systems to lipid nanoparticle platforms and controlled-release formulations — is reshaping how therapeutics reach patients. We cover the full spectrum of delivery technologies including inhalation devices, implantable systems, and targeted nanoparticle carriers.

Oncology & Immuno-Oncology

Oncology remains the largest therapeutic area by R&D investment. Our reports cover bispecific antibodies, antibody-drug conjugates, checkpoint inhibitors, CAR-T therapies, radiopharmaceuticals, and companion diagnostics with pipeline analysis and competitive positioning.

Biosimilars & Biologics

The biosimilar market is driven by patent cliffs of blockbuster biologics and increasing regulatory clarity. We analyze biosimilar development pipelines, interchangeability trends, market penetration dynamics, and the competitive strategies of both originator and biosimilar manufacturers.

Why Choose InsightAce for Pharmaceutical Market Intelligence?

  • Original primary research — 15–25 KOL interviews per report with pharma executives, CDMO leaders, formulators, and regulatory experts
  • 10-year market forecasts — analyst-built models with top-down and bottom-up triangulation, covering 2026–2035
  • Competitive landscape — detailed profiling of 15–25 companies per report including revenue analysis, pipeline mapping, and strategic positioning
  • Segmentation depth — by type, application, technology, formulation, route of administration, end-user, and region
  • Post-purchase support — dedicated analyst hours for follow-up questions, custom data tables, and presentation-ready slides

Frequently Asked Questions

How many pharmaceutical market research reports does InsightAce publish?

InsightAce Analytic has published 340+ pharmaceutical market research reports covering drug development, CDMO outsourcing, API manufacturing, biosimilars, clinical trials, and specialty pharma with 10-year forecasts.

What pharmaceutical sub-segments does InsightAce cover?

We cover CDMO & contract manufacturing, API & drug substance, drug delivery systems, oncology & immuno-oncology, biosimilars & biologics, cell & gene therapy, rare diseases & orphan drugs, CNS & neurology, and clinical trials & CRO markets.

What is included in InsightAce pharmaceutical reports?

Each report includes 10-year market size forecasts, competitive landscape with 15-25 company profiles, segmentation by type, application, and region, 15-25 KOL interviews, and post-purchase analyst support.

Can I customize a pharmaceutical report?

Yes. Every report purchase includes free 10% customization. You can add countries, extend the forecast period, add company profiles, or request specific segmentation cuts.

How do I request a sample pharmaceutical report?

Click "Request Sample" on any report card to receive an executive summary, table of contents, and sample data tables delivered to your email.